Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely ...

The trial failure reinforces Keytruda’s competitive position in first-line metastatic melanoma, where it already outperformed ...

This is the first commercial path to products made in space,” says Michael Reilly, Varda’s chief strategy officer. The ...

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...

Precigen's PAPZIMEOS wins early FDA approval with rapid insurer/physician uptake, a strong growth outlook, and improving EPS.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

NASA has enabled scientists to study the impact of microgravity on drug development for decades, beginning with the Space Shuttle. This work accelerated in the 2010s, with the completion of the ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination ...

US biotech Inhibrx Biosciences (Nasdaq: INBX) has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing ...